Synthetic cannabinoid availability on darknet drug markets—changes during 2016–2017

References

• Mounteney J, Oteo A, Griffiths P. The internet and drug markets: shining a light on these complex and dynamic systems. In: The internet and drug markets (European Monitoring Centre for Drugs and Drug Addiction: Insights 21). Luxembourg: Publications Office of the European Union; 2016.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction and Europol. Drugs and the darknet: perspectives for enforcement, research and policy. Luxembourg: EMCDDA–Europol Joint publications, Publications Office of the European Union; 2017.
   Google Scholar
• Ho JH, Wood DM, Archer JR, et al. Availability of prescription zopiclone over the internet. BMJ. 2015;351:h5710. DOI: 10.1136/bmj.h5710.
   PubMedGoogle Scholar
• Wood DM, Dargan PI. Using internet snapshot surveys to enhance our understanding of the availability of the novel psychoactive substance alpha-methyltryptamine (AMT). Subst Use Misuse. 2014;49:7–12.
   PubMed Web of Science ®Google Scholar
• Vermette-Marcotte AE, Dargan PI, Archer JR, et al. An internet snapshot study to compare the international availability of the novel psychoactive substance methiopropamine. Clin Toxicol (Phila). 2014;52:678–681. DOI: 10.3109/15563650.2014.933346.
   PubMed Web of Science ®Google Scholar
• Nizar H, Dargan PI, Wood DM. Using internet snapshot surveys to enhance our understanding of the availability of the novel psychoactive substance 4-methylaminorex and 4,4′-dimethylaminorex. J Med Toxicol. 2015;11:80–84. DOI: 10.1007/s13181-014-0425-0.
   Web of Science ®Google Scholar
• Home Office. Review of the Psychoactive Substances Act 2016. November 2018. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/756896/Review_of_the_Psychoactive_Substances_Act__2016___web_.pdf (last accessed 17 December 2018)
   Google Scholar
• Soska K, Christin N. Measuring the longitudinal evolution of the online anonymous marketplace ecosystem. In: Proceedings of the 24th USENIX Security Symposium, Washington, DC, 12–14 August; 2015. p. 33–48.
   Google Scholar
• United Nations Office on Drugs and Crime, World Drug Report. ISBN: 978-92-1-148291-1, eISBN: 978-92-1-060623-3, United Nations publication, Sales No. E.17.XI.6; 2017.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Synthetic cannabinoids in Europe (Perspectives on drugs); June 2017. http://www.emcdda.europa.eu/publications/pods/synthetic-cannabinoids_en (last accessed 13 December 2018)
   Google Scholar
• Joseph A, Lekas HM, Manseau M, et al. A polydrug and psychosocial profile of synthetic cannabinoid use in a New York City community sample, 2016–2017. Subst Use Misuse. 2018;7:1–6. DOI: 10.1080/10826084.2018.1517178.
   Google Scholar
• Wohlfarth A, Scheidweiler KB, Castaneto M, et al. Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. Clin Chem Lab Med. 2015;53(3):423–434. DOI: 10.1515/cclm-2014-0612.
   Google Scholar
• Ralphs R, Williams L, Askew R, et al. Adding spice to the porridge: the development of a synthetic cannabinoid market in an English prison. Int J Drug Policy. 2017;40:57–69. DOI: 10.1016/j.drugpo.2016.10.003.
   PubMed Web of Science ®Google Scholar
• Courts J, Maskill V, Gray A, et al. Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review. Australas Psychiatry. 2016;24:598–601.
   PubMed Web of Science ®Google Scholar
• Barutta F, Bruno G, Mastrocola R, et al. The role of cannabinoid signaling in acute and chronic kidney diseases. Kidney Int. 2018; pii: S0085-2538(18)30140-6. DOI: 10.1016/j.kint.2018.01.024
   Google Scholar
• Pacher P, Steffens S, Haskó G, et al. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2017;15:151–166.
   Web of Science ®Google Scholar
• Europol joint report on a new psychoactive substance: methyl 2-[[1-(cyclohexylmethyl) indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMBCHMICA). In: European Monitoring Centre for Drugs and Drug Addiction, Joint Reports Series. Luxembourg: Publications Office of the European Union; 2016.
   Google Scholar
• Adams AA, Banister SD, Irizarry L, et al. “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med. 2017;376:235–242.
   PubMed Web of Science ®Google Scholar
• Décary-Hétu D, Paquet-Clouston M, Aldridge J. Going international? Risk taking by cryptomarket drug vendors. Int J Drug Policy. 2016;35:69–76.
   Web of Science ®Google Scholar
• Broséus J, Rhumorbarbe D, Mireault C, et al. Studying illicit drug trafficking on darknet markets: structure and organisation from a Canadian perspective. Forens Sci Int. 2016;264:7–14. DOI:10.1016/j.forsciint.2016.02.045
   Web of Science ®Google Scholar
• Dolliver DS, Kenney JL. Characteristics of drug vendors on the Tor network: a cryptomarket comparison. Victims Offenders. 2016;11:600–620. DOI:10.1080/15564886.2016.1173158
   Web of Science ®Google Scholar
• Barratt MJ, Ferris JA, Winstock AR. Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States. Addiction. 2014;109:774–783. DOI: 10.1111/add.12470.
   PubMed Web of Science ®Google Scholar
• Winstock A, Barratt M, Ferris J, et al. Global drug survey; 2017. https://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2017_key-findings-report_final.pdf Slide 102 (last accessed 13 December 2018)
   Google Scholar
• Broséus J, Rhumorbarbe D, Morelato M, et al. A geographical analysis of trafficking on a popular darknet market. Forens Sci Int. 2017;277:88–102.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. European drug report 2017: trends and developments. Luxembourg: Publications Office of the European Union.
   Google Scholar
• Wilkins C, Rychert M, Byrska B, et al. Exploring innovative policy responses to NPS and ‘legal highs’ in New Zealand, Poland, Republic of Ireland and the UK. In: Novel psychoactive substances: policy, economics and drug regulation. Springer; p. 57–74.
   Google Scholar